Global Access Program for Ruconest

Netherlands-based Pharming Group has entered a partnership allowing access to its Ruconest (recombinant human C1 inhibitor) product for hereditary angioedema (HAE) to patients in all countries where it is not currently commercially available.

Together with the HAEi, the international umbrella organization for the world’s HAE patient groups, Pharming has teamed up with Inceptua Medicines Access as the new distribution partner for the HAEi Global Access Program.